Open AccessTUDCA prevents cholestasis and canalicular damage induced by ischemia‐reperfusion injury in the rat, modulating PKCα–ezrin pathway
Author(s) -
Baiocchi Leonardo,
Tisone Giuseppe,
Russo Mario Antonio,
Longhi Chiara,
Palmieri Gianpiero,
Volpe Antonio,
Almerighi Cristiana,
Telesca Claudia,
Carbone Marco,
Toti Luca,
Leonardis Francesco De,
Angelico Mario
Publication year - 2008
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/j.1432-2277.2008.00682.x
Subject(s) - cholestasis , ezrin , bone canaliculus , medicine , protein kinase c , bile acid , reperfusion injury , liver injury , tauroursodeoxycholic acid , endocrinology , ischemia , apoptosis , signal transduction , chemistry , cell , biochemistry , cytoskeleton , unfolded protein response
Summary Cholestasis, induced by liver ischemia‐reperfusion injury (IRI), is characterized by dilatation of bile canaliculi and loss of microvilli. Tauroursodeoxycholic acid (TUDCA) is an anti‐cholestatic agent, modulating protein kinase C (PKC) α pathway. PKC reduces ischemic damage in several organs, its isoform α modulates ezrin, a key protein in the maintenance of cell lamellipoidal extensions. We evaluated the effects of TUDCA on cholestasis, canalicular changes and PKCα–ezrin expression in a rat model of liver IRI. Livers flushed and stored with Belzer solution or Belzer + 10 m m TUDCA (4 °C for 6 h) were reperfused (37 °C with O 2 ) with Krebs–Ringer bicarbonate + 2.5 μmol/min of Taurocholate or TUDCA. Bile was harvested for bile flow assessment. Liver tissue was employed for Electron Microscopy (EM) and for PKCα and ezrin immunoblot and immunofluorescence. The same experiments were conducted with the PKCα inhibitor Go‐6976. TUDCA‐treated livers showed increased bile flow (0.25 ± 0.17 vs. 0.042 ± 0.02 μl/min/g liver, P < 0.05) and better preservation of microvilli and bile canalicular area at EM. These effects were associated with increased PKCα and ezrin expression ( P = 0.03 and P = 0.04 vs. control respectively), as also confirmed by immunofluorescence data. PKCα inhibition abolished these TUDCA effects. TUDCA administration during IRI reduces cholestasis and canalicular damage in the liver modulating PKCα–ezrin pathway.